Andere Sprachen Pulse Biosciences, Inc.

Aktien

A2AMY9

US74587B1017

PLSE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
7.37 ^USD	+1.66%		+7.43%	-39.79%

01.04.	Sektor-Update: Aktien des Gesundheitswesens rutschen am späten Nachmittag ab	MT
01.04.	Aktien von Pulse Biosciences fallen nach Q4-Ergebnissen und geplanter Bezugsrechtsemission	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024	24.04.
Sector Update: Health Care Stocks Slide Late Afternoon	01.04.
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01.04.
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results	28.03.
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.03.
Pulse Biosciences Announces Plans to Initiate a Rights Offering	28.03.
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024	14.03.
Sector Update: Health Care Stocks Ease Late Afternoon	08.03.
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	08.03.
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System	08.03.
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	08.03.
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY	15.02.
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	14.02.
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study	14.02.
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium	31.01.
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02.01.
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	02.01.
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	02.01.
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp	02.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Pulse Biosciences, Inc.

Aktien

A2AMY9

US74587B1017

PLSE

Andere Sprachen

Filter